BioAge Labs, Inc. (BIOA)
Data as of , from SEC Form 4 filings.
See up to 3 months of BIOA. The 7-day demo opens the 1M and 3M ranges and puts BIOA on your watchlist.
Start 7-day demoLatest BIOA insider trades
About BioAge Labs, Inc. (BIOA)
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
- EMERYVILLE, CA
- 62
- 2024
- XNAS
BIOA Form 4 activity by transaction type, last 90 days
No Form 4 activity for BIOA in the last 90 days.
BIOA insider transactions (Form 4)
7429 Form 4 filings on record, the earliest from Oct 1, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Shane Barton - Officer | Option exercise | Common Stock | 7,261 | $8.39 | $61K | |
| Shane Barton - Officer | Option exercise | Common Stock | 8,958 | $4.30 | $39K | |
| Shane Barton - Officer | Option exercise | Common Stock | 14,198 | $4.38 | $62K | |
| Shane Barton - Officer | Open-market sale | Common Stock | 42,350 | $25.21 footnote F2 | $1.07M | |
| Shane Barton - Officer | Option exercise | Common Stock | 4,290 | $10.85 | $47K | |
| Shane Barton - Officer | Option exercise | Common Stock | 4,000 | $8.39 | $34K | |
| Shane Barton - Officer | Option exercise | Common Stock | 4,065 | $4.30 | $17K | |
| Shane Barton - Officer | Option exercise | Common Stock | 7,861 | $4.38 | $34K | |
| Shane Barton - Officer | Open-market sale | Common Stock | 20,216 | $25.19 footnote F3 | $509K | |
| Shane Barton - Officer | Option exercise | Stock Option (Right to Buy) | 9,301 | $0.00 | - | |
| Shane Barton - Officer | Option exercise | Stock Option (Right to Buy) | 7,261 | $0.00 | - | |
| Shane Barton - Officer | Option exercise | Stock Option (Right to Buy) | 8,958 | $0.00 | - | |
| Shane Barton - Officer | Option exercise | Stock Option (Right to Buy) | 14,198 | $0.00 | - | |
| Shane Barton - Officer | Option exercise | Stock Option (Right to Buy) | 4,290 | $0.00 | - | |
| Shane Barton - Officer | Option exercise | Stock Option (Right to Buy) | 4,000 | $0.00 | - | |
| Shane Barton - Officer | Option exercise | Stock Option (Right to Buy) | 4,065 | $0.00 | - | |
| Shane Barton - Officer | Option exercise | Common Stock | 9,301 | $10.85 | $101K | |
| Shane Barton - Officer | Option exercise | Stock Option (Right to Buy) | 7,861 | $0.00 | - | |
| ||||||
| Vijay Satyanand Pande | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Rekha Hemrajani | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| James Healy | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Patrick G. Enright | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Michael H. Davidson | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Jean Pierre Garnier | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Dov A. Md Goldstein - Officer | Option exercise | Common Stock | 3,542 | $4.38 | $16K | |
| Dov A. Md Goldstein - Officer | Option exercise | Stock Option (Right to Buy) | 3,542 | $0.00 | - | |
| Paul D. Rubin - Officer | Option exercise | Common Stock | 5,437 | $4.11 | $22K | |
| Paul D. Rubin - Officer | Option exercise | Common Stock | 3,383 | $6.57 | $22K | |
| Paul D. Rubin - Officer | Open-market sale | Common Stock | 8,820 | $17.81 | $157K | |
| Paul D. Rubin - Officer | Option exercise | Stock Option (Right to Buy) | 5,437 | $0.00 | - | |
| Paul D. Rubin - Officer | Option exercise | Stock Option (Right to Buy) | 3,383 | $0.00 | - | |
| Paul D. Rubin - Officer | Open-market sale | Common Stock | 7,433 | $20.30 | $151K | |
| Paul D. Rubin - Officer | Option exercise | Stock Option (Right to Buy) | 5,433 | $0.00 | - | |
| Paul D. Rubin - Officer | Option exercise | Stock Option (Right to Buy) | 2,000 | $0.00 | - | |
| Paul D. Rubin - Officer | Option exercise | Common Stock | 5,433 | $4.11 | $22K | |
| Paul D. Rubin - Officer | Option exercise | Common Stock | 2,000 | $6.57 | $13K | |
| Dov A. Md Goldstein - Officer | Option exercise | Common Stock | 3,542 | $4.38 | $16K | |
| Dov A. Md Goldstein - Officer | Option exercise | Stock Option (Right to Buy) | 3,542 | $0.00 | - | |
| Paul D. Rubin - Officer | Grant or award | Stock Option (Right to Buy) | 110,000 | $0.00 | - | |
| Eric Morgen - Officer | Grant or award | Stock Option (Right to Buy) | 110,000 | $0.00 | - | |
| Eric Morgen - Officer | Grant or award | Stock Option (Right to Buy) | 12,500 | $0.00 | - | |
| Dov A. Md Goldstein - Officer | Grant or award | Stock Option (Right to Buy) | 110,000 | $0.00 | - | |
 Kristen Fortney - Officer | Grant or award | Stock Option (Right to Buy) | 330,000 | $0.00 | - | |
| Shane Barton - Officer | Grant or award | Stock Option (Right to Buy) | 45,000 | $0.00 | - | |
| Paul D. Rubin - Officer | Option exercise | Common Stock | 5,433 | $4.11 | $22K | |
| Paul D. Rubin - Officer | Option exercise | Common Stock | 2,000 | $6.57 | $13K | |
| Paul D. Rubin - Officer | Open-market sale | Common Stock | 7,433 | $18.75 | $139K | |
| Paul D. Rubin - Officer | Option exercise | Stock Option (Right to Buy) | 5,433 | $0.00 | - | |
| Paul D. Rubin - Officer | Option exercise | Stock Option (Right to Buy) | 2,000 | $0.00 | - | |
| Dov A. Md Goldstein - Officer | Option exercise | Common Stock | 3,541 | $4.38 | $16K | |
| Dov A. Md Goldstein - Officer | Option exercise | Stock Option (Right to Buy) | 3,541 | $0.00 | - | |
| Dov A. Md Goldstein - Officer | Option exercise | Common Stock | 3,542 | $4.38 | $16K | |
| Dov A. Md Goldstein - Officer | Option exercise | Stock Option (Right to Buy) | 3,542 | $0.00 | - | |
| Dov A. Md Goldstein - Officer | Option exercise | Common Stock | 27,000 | $8.39 | $227K | |
| Dov A. Md Goldstein - Officer | Open-market sale | Common Stock | 8,974 | $18.43 footnote F2 | $165K | |
| Dov A. Md Goldstein - Officer | Open-market sale | Common Stock | 4,440 | $19.45 footnote F3 | $86K | |
| Dov A. Md Goldstein - Officer | Open-market sale | Common Stock | 11,663 | $20.54 footnote F4 | $240K | |
| Dov A. Md Goldstein - Officer | Open-market sale | Common Stock | 1,923 | $21.08 footnote F5 | $41K | |
| Dov A. Md Goldstein - Officer | Option exercise | Stock Option (Right to Buy) | 27,000 | $0.00 | - | |
| ||||||
| Kristen Fortney - Officer | Open-market sale | Common Stock | 233,107 | $18.12 footnote F2 | $4.22M | |
| ||||||
| Paul D. Rubin - Officer | Option exercise | Common Stock | 68,897 | $4.11 | $283K | |
| Paul D. Rubin - Officer | Open-market sale | Common Stock | 68,897 | $10.19 footnote F2 | $702K | |
| Paul D. Rubin - Officer | Option exercise | Stock Option (Right to Buy) | 68,897 | $0.00 | - | |
| ||||||
| Vijay Satyanand Pande | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Patrick G. Enright | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| James Healy | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Jean Pierre Garnier | Grant or award | Stock Option (Right to Buy) | 22,000 | $0.00 | - | |
| Shane Barton - Officer | Grant or award | Stock Option (Right to Buy) | 40,000 | $0.00 | - | |
| Vijay Satyanand Pande | Open-market purchase | Common Stock | 126,793 | $19.73 | $2.50M | |
| Vijay Satyanand Pande | Open-market purchase | Common Stock | 67,096 | $19.73 | $1.32M | |
| Vijay Satyanand Pande | Open-market purchase | Common Stock | 25,306 | $19.90 | $504K | |
| Cormorant Asset Management, LP | Other | Common Stock | 1,179,529 | - | - | |
| Cormorant Asset Management, LP | Open-market purchase | Common Stock | 450,000 | $18.00 | $8.10M | |
| Cormorant Asset Management, LP | Other | Series D Redeemable Convertible Preferred Stock | 5,263,772 | - | - | |
Item 8.01
Item 2.02, 9.01
Item 5.07
Item 2.02, 9.01
Recent BIOA Form 144 notices of proposed sale
2An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - |
BIOA insider trading FAQ
What is the latest insider trade for BIOA?
BioAge Labs, Inc. (BIOA) has filed no insider reports in the last 90 days. The most recent on record is dated 2026-07-01. The full record for BIOA runs to 29 Form 4 filings, the earliest from 2024-10-01. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying BIOA stock?
No insider purchases of BIOA were filed in the last 90 days. 4 purchases are on record for this company.
How many insiders are selling BIOA stock?
No insider sales of BIOA were filed in the last 90 days. 11 sales are on record for this company.
Where can I see BIOA SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects BIOA Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Shane Barton view on EDGAR
- - Vijay Satyanand Pande view on EDGAR
- - Rekha Hemrajani view on EDGAR
- - James Healy view on EDGAR
- - Patrick G. Enright view on EDGAR
- - Michael H. Davidson view on EDGAR
- - Jean Pierre Garnier view on EDGAR
- - Dov A. Md Goldstein view on EDGAR
- - Paul D. Rubin view on EDGAR
Related companies with recent insider activity
Learn more
- What the Form 4 transaction codes mean
- Grants, option exercises, gifts and tax withholding are not trades on the market. The codes say which is which.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where BIOA's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow BIOA with a 7-day demo
- BIOA on your watchlist
- Every BIOA Form 4 filing on record
- Up to 3 months of BIOA price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.
